Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | DCAF1 | Q9Y4B6 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255107 | 0.94 | PTGER4 (0.41) | PTGER4PTGER2UTS2R | |
| SCHEMBL5926517 | 0.88 | CYP26A1 (0.41) | PTGER4PTGER2KCNA5 | |
| SCHEMBL4000018 | 0.85 | LMNA (0.40) | TACR3 | |
| SCHEMBL3977291 | 0.85 | PYGL (0.41) | TACR3 | |
| SCHEMBL3978720 | 0.85 | ITGA4 (0.44) | — | |
| SCHEMBL5926305 | 0.83 | CYP26A1 (0.44) | PTGER4KCNA5 | |
| SCHEMBL4831591 | 0.83 | TACR3 (0.44) | TACR3PTGER4PTGER2ROCK2ROCK1 | |
| SCHEMBL5926851 | 0.82 | TACR3 (0.44) | TACR3PTGER4PTGER2ROCK2ROCK1 | |
| SCHEMBL3979415 | 0.82 | TACR3 (0.44) | TACR3PTGER4PTGER2ROCK2ROCK1 | |
| SCHEMBL3994541 | 0.82 | KCNA5 (0.52) | KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | TACR3 3391/4885PTGER4 325/4885PTGER2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.